This report was first published by Endpoints News. To see the original version, click here
A new report trying to settle a decades-old debate about Alzheimer’s disease has reached a dramatic conclusion: Antibody drugs that target sticky amyloid beta proteins in the brain simply don’t work.
The meta-analysis, which compiles data from more than 20,000 patients across 17 clinical trials, determined that treatment with amyloid antibodies resulted in “little to no difference” in cognitive function, dementia severity and functional ability. The authors concluded that future Alzheimer’s drugs “should focus on other mechanisms of action.”
您已阅读8%（636字），剩余92%（7757字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。